{
    "root": "376e8626-79d8-4102-903d-104160f440b0",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium",
    "value": "20250314",
    "ingredients": [
        {
            "name": "Diclofenac Sodium",
            "code": "QTG126297Q",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE 101",
            "code": "7T9FYH5QMK",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        }
    ],
    "indications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration perforation ) . diclofenac sodium delayed-release tablets indicated : \u2022for relief signs symptoms osteoarthritis \u2022for relief signs symptoms rheumatoid arthritis \u2022for acute long-term relief signs symptoms ankylosing spondylitis",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "carefully consider potential benefits risks diclofenac sodium delayed-release tablets treatment options deciding diclofenac sodium delayed-release tablets . lowest effective dose shortest duration consistent individual patient treatment goals ( : gastrointestinal bleeding , ulceration , perforation ) . observing response initial therapy diclofenac sodium delayed-release tablets , dose frequency adjusted suit individual patient \u2019 needs . relief osteoarthritis , recommended 100 150 mg/day divided doses ( 50 mg twice day three times day , 75 mg twice day ) . relief rheumatoid arthritis , recommended 150 200 mg/day divided doses ( 50 mg three times day four times day , 75 mg twice day ) . relief ankylosing spondylitis , recommended 100 125 mg/day , administered 25 mg four times day , extra 25 mg dose bedtime necessary . different formulations diclofenac ( diclofenac sodium enteric-coated tablets ; diclofenac sodium extended-release tablets ; diclofenac potassium immediate-release tablets ) necessarily bioequivalent even milligram strength .",
        "doid_entities": [
            {
                "text": "osteoarthritis (DOID:8398)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8398"
            },
            {
                "text": "rheumatoid arthritis (DOID:7148)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7148"
            },
            {
                "text": "arthritis (DOID:848)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_848"
            },
            {
                "text": "ankylosing spondylitis (DOID:7147)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_7147"
            },
            {
                "text": "spondylitis (DOID:6590)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6590"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "supplied diclofenac sodium delayed-release tablets , usp , oral , available : 75 mg : round , light brown , enteric-coated tablets p 75 imprinted one side black ink plain reverse side supplied : bottles 30. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 68788-8193-3 bottles 60. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 68788-8193-6 bottles 90. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 68788-8193-9 bottles 100. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 68788-8193-1 bottles 120. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ndc 68788-8193-8 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ( usp controlled room temperature ) . protect moisture . dispense tight , light-resistant container . manufactured : unique pharmaceutical laboratories ( div . j. b. chemicals & pharmaceuticals ltd. ) , mumbai 400 030 , india . distributed : rising pharma holdings , inc. east brunswick , nj 08816 1-800-521-5340 139661 jul . 2024 repackaged : preferred pharmaceuticals inc .",
    "adverseReactions": "diclofenac sodium delayed-release tablets contraindicated following patients . \u2022known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac components product ( : anaphylactic , serious skin ) . \u2022history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients ( : anaphylactic reaction , exacerbation asthma related aspirin sensitivity ) . \u2022in setting coronary artery bypass graft ( cabg ) surgery ( : cardiovascular thrombotic events ) .",
    "indications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration and Perforation\n                     ).\n                  Diclofenac sodium delayed-release tablets are indicated:\n                  \n                     \n                        \u2022For relief of the signs and symptoms of osteoarthritis\n                     \n                        \u2022For relief of the signs and symptoms of rheumatoid arthritis\n                     \n                        \u2022For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis",
    "contraindications_original": "Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see \n                        WARNINGS: Gastrointestinal Bleeding, Ulceration, and Perforation\n                     ).\n                  After observing the response to initial therapy with diclofenac sodium delayed-release tablets, the dose and frequency should be adjusted to suit an individual patient\u2019s needs.\n                  For the relief of osteoarthritis, the recommended dosage is 100 to 150 mg/day in divided doses (50 mg twice a day or three times a day, or 75 mg twice a day).\n                  For the relief of rheumatoid arthritis, the recommended dosage is 150 to 200 mg/day in divided doses (50 mg three times a day or four times a day, or 75 mg twice a day).\n                  For the relief of ankylosing spondylitis, the recommended dosage is 100 to 125 mg/day, administered as 25 mg four times a day, with an extra 25 mg dose at bedtime if necessary.\n                  Different formulations of diclofenac (diclofenac sodium enteric-coated tablets; diclofenac sodium extended-release tablets; diclofenac potassium immediate-release tablets) are not necessarily bioequivalent even if the milligram strength is the same.",
    "warningsAndPrecautions_original": "HOW SUPPLIED\n                      Diclofenac sodium delayed-release tablets, USP, for oral administration, are available as:\n                  \n                     75 mg: round, light brown, enteric-coated tablets\n                         \u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 P\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 75\n                     imprinted on one side in black ink and plain on the reverse side are supplied as:\n                  \n                     Bottles of 30.........................................NDC 68788-8193-3\n                  Bottles of 60.........................................NDC 68788-8193-6\n                  Bottles of 90.........................................NDC 68788-8193-9\n                  Bottles of 100.........................................NDC 68788-8193-1\n                  Bottles of 120.........................................NDC 68788-8193-8\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) (see USP Controlled Room Temperature). Protect from moisture. Dispense in a tight, light-resistant container.\n                  \n                     Manufactured by:Unique Pharmaceutical Laboratories (A Div. of J. B. Chemicals & Pharmaceuticals Ltd.), Mumbai 400 030, India.\n                  \n                     Distributed by:\n                  \n                  \n                  Rising Pharma Holdings, Inc.\n                  East Brunswick, NJ 08816\n                   1-800-521-5340\n                      139661\n                  Jul. 2024\n                  \n                     Repackaged By: Preferred Pharmaceuticals Inc.",
    "adverseReactions_original": "Diclofenac sodium delayed-release tablets are contraindicated in the following patients.\n                  \n                     \n                        \u2022Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see \n                           WARNINGS: Anaphylactic Reactions\n                        , \n                           Serious Skin Reactions\n                        ).\n                     \n                        \u2022History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients (see \n                           WARNINGS: Anaphylactic Reaction\n                        , \n                           Exacerbation of Asthma Related to Aspirin Sensitivity\n                        ).\n                     \n                        \u2022In the setting of coronary artery bypass graft (CABG) surgery (see \n                           WARNINGS: Cardiovascular Thrombotic Events).",
    "drug": [
        {
            "name": "Diclofenac Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4509"
        }
    ]
}